Asciminib in Newly Diagnosed Chronic Myeloid Leukemia-Reference-Cited by-同舟云学术

Asciminib in Newly Diagnosed Chronic Myeloid Leukemia

Published:2024-09-12 Issue:10 Volume:391 Page:885-898
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Hochhaus Andreas¹,Wang Jianxiang¹,Kim Dong-Wook¹,Kim Dennis Dong Hwan¹,Mayer Jiri¹,Goh Yeow-Tee¹,le Coutre Philipp¹,Takahashi Naoto¹,Kim Inho¹,Etienne Gabriel¹,Andorsky David¹,Issa Ghayas C.¹,Larson Richard A.¹,Bombaci Felice¹,Kapoor Shruti¹,McCulloch Tracey¹,Malek Kamel¹,Yau Lillian¹,Ifrah Sophie¹,Hoch Matthias¹,Cortes Jorge E.¹,Hughes Timothy P.¹

Affiliation:

1. From Klinik für Innere Medizin II, Hematology/Oncology, Universitätsklinikum Jena and Comprehensive Cancer Center Central Germany, Campus Jena, Jena (A.H.), and the Department of Oncology and Hematology, Charité-Universitätsmedizin Berlin, Berlin (P.C.) — both in Germany; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College,...

Funder

Novartis Pharma AG

Publisher

Massachusetts Medical Society

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa2400858

Reference40 articles.

1. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

2. Expert opinion—management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors

3. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

4. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

5. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CML 25 Years Later — Poised for Another Breakthrough?;New England Journal of Medicine;2024-09-12

2. Real-World Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System Database for Asciminib;Oncology;2024-08-05

3. Optimal frontline therapy of chronic myeloid leukemia today, and related musings;American Journal of Hematology;2024-08-02

4. Asciminib: the next-generation bullet for first-line treatment of chronic myeloid leukemia;Med;2024-08

5. Absence of ABL1 exon 2-encoded SH3 residues in BCR::ABL1 destabilizes the autoinhibited kinase conformation and confers resistance to asciminib;Leukemia;2024-07-31